Migalastat hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for migalastat hydrochloride and what is the scope of patent protection?
Migalastat hydrochloride
is the generic ingredient in one branded drug marketed by Amicus Therap Us and is included in one NDA. There are fifty-eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.Migalastat hydrochloride has two hundred and thirty-three patent family members in thirty countries.
One supplier is listed for this compound.
Summary for migalastat hydrochloride
| International Patents: | 233 |
| US Patents: | 58 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 41 |
| Clinical Trials: | 20 |
| Patent Applications: | 163 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for migalastat hydrochloride |
| What excipients (inactive ingredients) are in migalastat hydrochloride? | migalastat hydrochloride excipients list |
| DailyMed Link: | migalastat hydrochloride at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for migalastat hydrochloride
Generic Entry Date for migalastat hydrochloride*:
Constraining patent/regulatory exclusivity:
INDICATED FOR THE TREATMENT OF ADULTS WITH A CONFIRMED DIAGNOSIS OF FABRY DISEASE AND AN AMENABLE GALACTOSIDASE ALPHA GENE (GLA) VARIANT BASED ON IN VITRO ASSAY DATA Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for migalastat hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Genzyme, a Sanofi Company | Phase 3 |
| Amicus Therapeutics | Phase 1 |
| Amicus Therapeutics | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for migalastat hydrochloride
Paragraph IV (Patent) Challenges for MIGALASTAT HYDROCHLORIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| GALAFOLD | Capsules | migalastat hydrochloride | 123 mg | 208623 | 3 | 2022-08-10 |
US Patents and Regulatory Information for migalastat hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therap Us | GALAFOLD | migalastat hydrochloride | CAPSULE;ORAL | 208623-001 | Aug 10, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Amicus Therap Us | GALAFOLD | migalastat hydrochloride | CAPSULE;ORAL | 208623-001 | Aug 10, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Amicus Therap Us | GALAFOLD | migalastat hydrochloride | CAPSULE;ORAL | 208623-001 | Aug 10, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Amicus Therap Us | GALAFOLD | migalastat hydrochloride | CAPSULE;ORAL | 208623-001 | Aug 10, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Amicus Therap Us | GALAFOLD | migalastat hydrochloride | CAPSULE;ORAL | 208623-001 | Aug 10, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Amicus Therap Us | GALAFOLD | migalastat hydrochloride | CAPSULE;ORAL | 208623-001 | Aug 10, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for migalastat hydrochloride
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2019510030 | ＧＬＡ遺伝子にＧ９３３１Ａ変異を有する患者においてファブリー病を処置する方法 | ⤷ Sign Up |
| Australia | 2016206297 | METHOD TO PREDICT RESPONSE TO PHARMACOLOGICAL CHAPERONE TREATMENT OF DISEASES | ⤷ Sign Up |
| European Patent Office | 4062915 | MIGALASTAT ATTACHÉ À ALPHA GALACTOSIDASE A (MIGALASTAT BOUND TO ALPHA GALACTOSIDASE A) | ⤷ Sign Up |
| European Patent Office | 3457135 | OPTIONS DE TRAITEMENT POUR LA MALADIE DE FABRY (TREATMENT OPTIONS FOR FABRY DISEASE) | ⤷ Sign Up |
| Australia | 2019217868 | Use of migalastat for treating fabry disease in pregnant patients | ⤷ Sign Up |
| Canada | 3224537 | METHODES DE TRAITEMENT DE PATIENTS ATTEINTS DE LA MALADIE DE FABRY SOUFFRANT D'UNE INSUFFISANCE RENALE (USE OF MIGALASTAT IN THE TREATMENT OF FABRY PATIENTS HAVING RENAL IMPAIRMENT) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for migalastat hydrochloride
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2787345 | 93312 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: MIGALASTAT OU UN SEL DE CELUI-CI , Y COMPRIS LE SEL DE CHLORHYDRATE; AUTHORISATION NUMBER AND DATE: EU/1/15/1082 - GALAFOLD - MIGALASTAT |
| 2787345 | 2016/050 | Ireland | ⤷ Sign Up | PRODUCT NAME: MIGALASTAT OR A SALT THEREOF, INCLUDING THE HYDROCHLORIDE SALT; REGISTRATION NO/DATE: EU/1/15/1082 20160526 |
| 2787345 | 1690052-4 | Sweden | ⤷ Sign Up | PRODUCT NAME: MIGALASTAT OR A SALT THEREOF, INCLUDING THE HYDROCHLORIDE SALT.; REG. NO/DATE: EU/1/15/1082 20160531 |
| 2787345 | 268 5025-2016 | Slovakia | ⤷ Sign Up | PRODUCT NAME: MIGALASTAT VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/15/1082 20160531 |
| 2787345 | 634 | Finland | ⤷ Sign Up | |
| 2787345 | C20160037 00206 | Estonia | ⤷ Sign Up | PRODUCT NAME: MIGALASTAAT;REG NO/DATE: EU/1/15/1082 31.05.2016 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
